TNXP

Tonix Pharmaceuticals Holding Corp

The late-stage candidate TNX-102 SL has received FDA Fast Track status and has delivered positive results in two pivotal Phase 3 trials, demonstrating meaningful pain reduction.

The proceeds from the purchase agreement are expected to be used for working capital and general corporate purposes.

In his role at Celgene Corp, Hand played a strategic role in transactions including the $74 billion acquisition of Celgene by Bristol Myers Squibb and its subsequent integration.

Tonix CEO Seth Lederman remains optimistic with the launch of a new drug for the management of pain in Fibromyalgia patients in the pipeline for the fourth quarter (Q4) of 2025.

Short interest in the stock has grown steadily since mid-December, rising from 0.9% to 8.5% by the end of January, according to Koyfin data.

From Tonix Pharmaceuticals’ progress on fibromyalgia treatments to Nvidia-backed Recursion Pharmaceuticals, these stocks sparked significant message volume growth on Stocktwits.

The drug already received Fast Track designation in July 2024, expediting the review process due to its potential to address an unmet medical need.

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.

Among the four U.S.-listed pharma stocks, retail investors are ‘extremely bullish’ on Emergent Biosolutions as it expressed readiness to scale up response efforts for the WHO health emergency.